Roche strikes second Orionis deal to develop ‘molecular glues’ for cancer
The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body of destructive proteins that are hard to target by other means.
The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body of destructive proteins that are hard to target by other means.
